By
Oak Therapeutics
Published: Oct. 4, 2017, 11:44 p.m.·
Tags:
Pediatrics,
Treatment,
Scientific research
Results of in vivo study signifies completion of another critical milestone in company’s Phase I of NIAID contract* to develop ODS strip for anti-tuberculosis treatment option.
Read More →